Brain tumor cocktail: could a 4-Drug combo tame glioblastoma?
NCT ID NCT05083754
First seen Jan 09, 2026 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This early-stage trial is testing whether combining a chemotherapy wafer placed in the brain during surgery with an immunotherapy drug and standard radiation (with or without another chemo pill) is safe and feasible for people with newly-diagnosed glioblastoma. About 50 adults who have already had the wafer placed will receive the combination. The main goal is to find the safest dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins Medical Institution
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
carmustine wafer, retifanlimab, temozolomide, radiation therapy
What this could lead to
If this works, it could point toward a more effective treatment for glioblastoma that combines chemotherapy, immunotherapy, and radiation.
What could go wrong
This is a very early Phase 1 trial with only 50 people, so it is mainly checking safety and dosing. The combination may cause serious side effects and might not improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.